News Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:16:17 10/04/2026 BST			5-day change	1st Jan Change
14.64 ^AUD	+7.33%		+13.05%	+30.71%

04-10	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus	MT
04-10	Top Premarket Gainers	MT

All News

04-10	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus	MT
04-10	Top Premarket Gainers	MT
04-10	Telix Pharmaceuticals Says FDA Accepted Brain Cancer Imaging Application; Shares Rise Pre-Bell	MT
04-10	Telix Pharmaceuticals Says FDA Accepted Brain Cancer Imaging Application	MT
04-10	Telix Pharmaceuticals Limited Announces FDA Acceptance Of Resubmitted New Drug Application For TLX101-Px1 (Pixclara®)	CI
04-10	Telix Pharmaceuticals says FDA accepts NDA for Tlx101-Px (Pixclara)	RE
04-10	Australian shares edge lower as miners retreat, markets await Middle East talks	RE
04-10	Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent	MT
04-09	FDA Accepts NDA for TLX101-Px (Pixclara®)	AQ
04-09	Telix Pharmaceuticals Limited Announces Board Appointments, Effective May 11, 2026	CI
04-08	Telix Strengthens Board with Additional Director Appointments	AQ
04-08	Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy	MT
04-07	Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies	MT
04-07	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline	MT
04-07	Telix Pharmaceuticals Q1 Revenue Rises; Full-Year Sales Outlook Reaffirmed -- Shares Up Pre-Bell	MT
04-07	Telix Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2026	CI
04-07	Telix pharmaceuticals posts Q1 2026 unaudited group revenue of US$230 million	RE
04-07	Telix Pharmaceuticals Q1 Revenue Rises 24%; Shares Gain 6%	MT
04-06	Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement	PU
04-02	Telix Pharmaceuticals Limited Appoints David Gill as Non-Executive Director, Effective May 11, 2026	CI
04-02	Telix pharmaceuticals appoints David Gill as non-executive director	RE
04-02	Telix Pharmaceuticals : Appoints David Gill as Non-Executive Director	PU
03-27	ASX Biggest Gainers	MT
03-20	Grand Pharmaceutical Group Limited Provides Earnings Guidance for the Year Ended December 31, 2025	CI
03-20	Ion Beam Applications Bags Fixed-energy Cyclotrons Supply Order	MT